Close
Close

Peking University - Multiple Myeloma

Partner

Not provided

Rare Disease

Multiple Myeloma

Sponsor

Peking University

Access Program Information

Multiple Myeloma (MM) is the second diagnosed malignancy of hematological malignancies. The previous study pointed out that the dosage and course of Bortezomib including the dose of concomitant drugs used to treatment MM patients did not get the preferred treatment program, so we are going to determine the optimal doses and course of Bortezomib through the prospective, multicenter clinical trial and evaluate the efficiency and safety of different program.

Contact

Contact: (+86-13701389625)

Locations
  • China

Free Newsletter